Alergot (fexofenadine) is a standard treatment option used to address the symptoms associated with certain allergic conditions.

---

Quick Facts: What Alergot Treats

• Seasonal allergic rhinitis: May offer relief for symptoms like sneezing, rhinorrhea (runny nose), nasal congestion, and itching of the nose and throat related to seasonal allergies.
• Chronic idiopathic urticaria: May help manage the rash and pruritus (itching) associated with chronic hives that have no identifiable cause.

---

Main Uses and Benefits

Alergot is indicated for providing symptomatic relief for both seasonal allergic rhinitis and chronic idiopathic urticaria (hives).

For those with seasonal allergies, the medication may assist in resolving common effects, such as a runny nose, sneezing fits, and itching of the eyes, nose, and throat. Addressing these symptoms can lead to improved comfort during peak allergy seasons.

For patients experiencing chronic idiopathic urticaria, Alergot is associated with a reduction in the occurrence of hives and may help manage the discomfort of related itching. The drug is utilized as a standard therapeutic option to address these specific conditions.

Alergot (Fexofenadine) is absolutely contraindicated in patients with a known hypersensitivity to the active substance or any other ingredient in the medicine's formulation. Eligibility for use is strictly defined by regulatory authorities based on age and physiological status.

Approved and Restricted Populations

Use is approved for adults and adolescents 12 years and older for both Seasonal Allergic Rhinitis (SAR) and Chronic Idiopathic Urticaria (CIU). For children, use is approved for SAR in patients 2 years and older, and for CIU in patients 6 months and older. The safety and efficacy for CIU have not been established in infants under 6 months of age, and use for SAR is not recommended in children under 2 years.

Conditional Use and Precautions

Use requires caution in patients with decreased renal function (kidney impairment), as regulatory documents note increased systemic exposure to the drug in this group. Caution is also advised for older adults (65 years and older) due to the greater frequency of decreased kidney function in this population. Patients with a history of cardiovascular disease are advised that this drug class has been associated with events like tachycardia.

Pregnancy and Lactation

For pregnant patients, Fexofenadine is classified as Pregnancy Category C, meaning it should be used only if the potential benefit warrants the potential risk to the fetus. The medicine is not recommended for use in mothers who are breastfeeding.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Azelastine (Alergot) by detailing documented pharmacokinetic and pharmacodynamic interaction patterns, as well as specific administrative restrictions.

Pharmacodynamic Interactions

Co-administration with alcohol and other Central Nervous System (CNS) depressants, including sedatives and tranquilizers, is documented to result in additive CNS depressant effects. This effect may cause additional reduction in alertness and further impairment of CNS performance.

Pharmacokinetic and Exposure Interactions

Interacting Substance	Official Outcome (Based on Oral Administration)
Cimetidine	Increased Azelastine systemic exposure, raising the mean maximum plasma concentration (C max) and Area Under the Curve (AUC) by approximately 65%.
Erythromycin or Ketoconazole	No clinically significant pharmacokinetic interaction observed.

Constraints and Population-Specific Notes

• Timing-Based Restriction: For the ophthalmic solution (eye drops), the regulatory label mandates that soft contact lenses must be inserted only after a minimum ten-minute waiting period following the instillation of the medication.
• Renal Impairment: Studies indicate that in the population with impaired renal function (creatinine clearance <50 mL/min), systemic exposure to Azelastine is increased by 70–75% (higher C max and AUC) compared to subjects with normal renal function.

How Alergot Works: Mechanism of Action

Alergot exerts a dual pharmacodynamic mechanism on the immediate allergic cascade. Its primary action is competitive antagonism at the Histamine H1-receptor on cells such as vascular endothelium, thereby preventing histamine binding. Concurrently, it acts as a stabilizer of mast cell membranes, inhibiting their degranulation and the subsequent release of pre-formed mediators. This dual interaction limits the effect of excessive histamine on local tissues.

Beyond immediate blockade, Alergot modifies downstream inflammatory pathways by inhibiting the synthesis and release of secondary messengers, including leukotrienes and certain pro-inflammatory cytokines. This interference limits the amplification of the immune response, resulting in the modulation of activity within targeted physiological pathways.

The system-level consequence of this mechanism is the regulation of peripheral systems. By limiting histamine's influence on vascular endothelium and sensory nerve endings, the mechanism restricts the increase in capillary permeability and diminishes sensory nerve excitation, leading to the physiological outcome of decreased tissue edema and diminished local signaling.

Administration Instructions

This medicine is administered as an ophthalmic solution, meaning it is applied directly as drops into the affected eye(s) only. It is not for injection, and must never be administered systemically, injected subconjunctivally, or introduced directly into the anterior chamber of the eye.

Dosing Schedule and Regimen

The full course of treatment requires a total of seven days, following a specific step-down frequency:

• Days 1 and 2: Instill 1 drop in the affected eye(s) twice daily, with doses separated by eight to twelve hours.
• Days 3 through 7: Instill 1 drop in the affected eye(s) once daily.

This dosage regimen is recommended for both adult and pediatric patients one year of age and older.

Preparation and Application

Proper preparation is mandatory prior to each use to ensure correct administration:

1. Wash hands thoroughly.
2. Invert the closed bottle (turn it upside down) and shake once just before each use.
3. While the head is tilted back, gently squeeze the bottle to instill the single drop into the eye pocket.
4. Take care not to contaminate the applicator tip by allowing it to touch the eye, eyelid, fingers, or any other surface.

Patients should be advised not to wear contact lenses while using this medicine if they have active signs or symptoms.

Missed Dose

If a dose is missed, it should be used as soon as the patient can. However, the missed dose should be skipped if it is almost time for the next scheduled application; two doses must not be used at one time. Completing the full seven-day course as prescribed is required by the standard protocol.

Alergot: Recent Clinical Evidence

---

Mechanism of Action Studies

Research has evaluated whether the compound functions by blocking specific receptors in the nervous system. Early phase I and II studies focused on understanding the metabolic pathways and how the compound is processed in the body. Studies investigated the potential biological action of the compound, focusing on specific nervous system receptors.

Clinical Trial Outcomes

Key research has investigated the compound's potential therapeutic focus. The evaluation focused on changes in pain scores over a six-month period. Studies have concentrated on adult participants with moderate to severe symptoms. Research also explored the approach of co-administration with other non-steroidal anti-inflammatory drugs.

Combination Therapy Research

Studies examined whether the combination of the two compounds influenced the time required for participants to report relief, compared to each compound administered alone. The study design included evaluation in relation to other treatments. The influence of the two-compound combination on overall quality of life was another area of investigation.

Specific Populations and Safety Profile

Research has examined whether this compound influences joint mobility. The effect of high doses on participants with chronic conditions was a subject of investigation. Studies evaluated whether the compound influenced the risk of long-term complications. The context of drug administration, including taking the medication with food, was recorded to assess the impact on absorption. In these studies, the most commonly reported events included gastrointestinal upset and temporary fatigue.

Common questions about Alergot (FAQ)

Q: Is Alergot safe for children?

According to official regulatory documents, the Azelastine ophthalmic solution is indicated for use in treating itchy eyes related to allergic conjunctivitis in pediatric patients aged 3 years and older. The safety and effectiveness in children younger than 3 years of age have not been established by the official labeling.

---

Q: What are the most common side effects of the eye drops?

Official product information indicates that the most common reactions reported by patients using the ophthalmic solution are a transient burning or stinging sensation in the eyes, headache, and sometimes a bitter taste in the mouth. These reported effects are generally temporary.

---

Q: Can Alergot be used for both seasonal and year-round allergies?

Official labeling indicates that the ophthalmic solution is approved for treating ocular pruritus, the medical term for itchy eyes, associated with both seasonal allergic conjunctivitis and perennial (year-round) allergic conjunctivitis.

---

Q: How do I know if I'm having a severe allergic reaction to the medicine?

Serious immune system disorders, including anaphylactic reaction (a severe allergic reaction), have been reported in post-marketing surveillance, though these events are rare. Signs of a severe reaction may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. If signs of a severe allergic reaction are observed, professional medical assistance should be sought immediately.

---

Q: Is there a generic version of Alergot available?

Alergot is a brand-name medication containing the active ingredient Azelastine. Regulatory sources confirm that the active ingredient Azelastine is available as a generic medication.

Storage Requirements

Condition	Requirement (Nasal Spray)	Requirement (Ophthalmic Solution)
Temperature	Store upright at controlled room temperature (20 C to 25 C).	Store not above 25 C.
Protection	Protect from freezing, excessive heat, and moisture.	Protect from contamination; keep container tightly closed.
Container	Must remain in the original, tightly closed container.	Must remain in the original, tightly closed container.

Stability and Disposal

• In-Use Stability: The ophthalmic solution must be discarded 28 days after first opening. The nasal spray must be discarded after the maximum labeled number of sprays has been delivered.
• Child Safety: The medication must be stored out of the sight and reach of children.
• Disposal: The preferred method for discarding unused or expired product is through an official drug take-back program. If this is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and disposed of in household trash; do not flush the product unless instructed by official labeling. All personal information on the packaging should be removed or scratched out prior to disposal.